Pricing Log in Create free account
Friday 6 November 2026 Export PBH’s income statement to Excel — free account

Prestige Consumer Healthcare Inc.

PBH Healthcare Drug Manufacturers Specialty & Generic

Prestige Consumer Healthcare Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 billion, down 4.31% from fiscal 2025.

Revenue
+22.7%
EPS
−38.4%
Free cash flow
−38.2%
Total debt
+100.9%

Quarter to September 2026, against a year earlier

44.63 8.65 −16.23%
Market cap
$2.1B
P/E
13.7×
Fwd P/E
11.7×
Dividend yield
—
F-score
5/9
Altman Z
2.48
Beneish M
−2.53
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Prestige Consumer Healthcare Inc. (PBH) EV/EBITDA

Alert me on EV/EBITDA

As of 5 November 2026, Prestige Consumer Healthcare Inc. (PBH) trades at a EV/EBITDA of 12.4×. Over the past ten years it has ranged from 9.2× (June 2026) to 387× (August 2023); the current reading is higher than 33% of that period. That is in line with the Drug Manufacturers Specialty & Generic industry median of 12.2× and above the Healthcare sector median of 8.4×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2026 11.2× (20.67%)
FY2025 14.1× 14.55%
FY2024 12.3× (95.95%)
FY2023 304× 2,595.69%
FY2022 11.3× 1.87%
FY2021 11.1× 2.08%
FY2020 10.8× (65.56%)
FY2019 31.4× 116.00%
FY2018 14.6× (31.53%)
FY2017 21.3× 40.82%

Quarterly newest first

Period EV/EBITDA Change
Sep 2026 12.6× (2.50%)
Jun 2026 12.9× 15.49%
Mar 2026 11.2× 0.22%
Dec 2025 11.2× 2.23%
43 more quarters

Against its own ten years

Low 9.2× High 387×
Ten-year median 14.0×
Current reading's percentile 33

EV/EBITDA against peers

Company EV/EBITDA
PRGO Perrigo Company plc compare n/m
BCRX BioCryst Pharmaceuticals, Inc. compare n/m
ALVO Alvotech compare n/m
AMLX Amylyx Pharmaceuticals, Inc. compare n/m
TRLV Trulieve Cannabis Corp. compare n/m
HCM HUTCHMED (China) Limited Sponsored ADR compare 0.4×
RGC Regencell Bioscience Holdings Limited compare 1.1×
PBH Prestige Consumer Healthcare Inc. 12.4×
XERS Xeris Biopharma Holdings, Inc. compare 46.6×
Drug Manufacturers Specialty & Generic industry median 12.2×
Healthcare sector median 8.4×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on PBH